Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 1996 / Cilt: 2 - Sayı: 3
Postmenopozal meme kanserli hastalarda tamoksifen'in endometriyum üzerine etkileri
- Pages
- 215–218
- DOI
- —
Abstract
OBJECTIVE: To assess the effects of tamoxifen on endometrium in postmenopausal breast cancer patients. STUDY DESIGN: Forty-seven gynecologically asymptomatic postmenopausal breast cancer patients were studied. Twenty-six patients had been treated with tamoxifen for at least 6 months and 21 had not received any hormonal treatment. The two groups were similar in age, parity, age at menopause and body mass index. RESULTS: The mean ultrasonographic endometrial thicknesses in tamoxifen-treated and nontreated patients were 7.9±5.8 mm and 3.7±2.0 mm respectively; the difference was statistically significant (p<0.05). The frequency of endometrial pathologic changed in the endometrial samplings was significantly higher (30.7%) among the tamoxifen-treated patients, compared with nontreated patients (4.7%) (p<0.05). In tamoxifen group, pathologic endometrial findings were observed in 8 (30.7%) patients. Of these women 5 (19.2%) had an endometrial polyp, 2 (7.7%) had endometrial cystic hyperplasia and 1 (3.8%) had endometrial cancer. In control group, pathologic endometrial change was diagnosed in 1 (4.7%) patient who had endometrial cystic hyperplasia. CONCLUSION: Our findings indicate a significant correlation between tamoxifen treatment and pathologic endometrial changes in postmenopausal breast cancer patients. We therefore recommend that postmenopausal patients receiving tamoxifen have periodic endometrial samplings.
Özet
Jinekolojik olarak asemptomatik 47 postmenopozal meme kanserli hastada, tamoksifen'in endometriyum üzerine etkileri araştırıldı. Hastalardan 26'sı en az 6 ay süre ile tamoksifen kullanmaktaydı. Kontrol grubunu oluşturan 21 hasta ise herhangi bir hormonal tedavi almamaktaydı. Tamoksifen alan hastalarda ortalama endometriyal kalınlık 7.9+5.8 mm, kontrol grubunda 3.7+2.0 mm olarak bulundu; aradaki fark istatistiksel olarak anlamlı idi (p<0.05). Endometriyal örneklemelerde, tamoksifen alan hastaların 8 inde (%30.7) patolojik değişiklikler saptanrken, kontrol grubunda 1 hastada (%4.7) patolojik bulgu mevcuttu; aradaki fark istatistiksel olarak anlamlı idi. (p<0.05). Bu bulgularla, tamoksifen kullanan postmenopozal hastalarn peryodik endometriyal biyopsilerle takip edilmeleri gerektiği sonucuna varıldı.